ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00312442
Recruitment Status : Terminated (STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it safer and better candidate for therapeutic applications.)
First Posted : April 10, 2006
Last Update Posted : June 2, 2010
Sponsor:
Information provided by:
STEBA France

Brief Summary:
The aim of this clinical trial is to evaluate the efficacy and safety of the WST09-mediated vascular-targeted photodynamic therapy (VTP) in patients with localized prostate cancer recurrent after external radiation therapy or temporary (High Dose Rate, or HDR) brachytherapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Treatment with WST09 Vascular Photodynamic therapy Phase 2 Phase 3

Detailed Description:

This is a multicentre, open labelled, phase II/III, 6-month clinical trial with an additional follow-up at Month 12, aiming to determine the efficacy and tolerability of the WST09-mediated VTP treatment. This treatment consists of an I.V. infusion of WST09 (2 mg/kg), in combination with per-cutaneous interstitial illumination using laser light (wavelength at 763nm) delivered through optical fibres positioned through the perineum in the prostatic lobes.

Patients who are eligible to participate in the study must have a clinically diagnosed positive biopsy of the prostate (up to stage T2b-N0-M0) diagnosed after external radiotherapy or temporary brachytherapy (no seeds), and present with increasing PSA levels on three consecutive occasions (at least 3 months apart) post-radiation treatment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy
Study Start Date : May 2006
Actual Primary Completion Date : July 2008
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: WST 09
Treatment with WST09-mediated VTP
Drug: Treatment with WST09 Vascular Photodynamic therapy



Primary Outcome Measures :
  1. Prostate biopsy results at Month 6 after treatment. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Percentage of positive cores in the biopsies prior to and 6 months after the WST09-mediated VTP. [ Time Frame: 6 months ]
  2. PSA levels taken periodically for 1 year after the procedure [ Time Frame: Month 1,3,6 and 1 year ]
  3. Hypoperfusion according to MRI at Week 1 after the procedure. [ Time Frame: 1 week and Month 6 ]
  4. Calculated PSA velocity before and after WST09-mediated VTP. [ Time Frame: Month 1,3,6 and 1 year ]
  5. Nadir of the PSA after the WST09-mediated VTP compared with the nadir of PSA after radiation therapy [ Time Frame: Month 1,3,6 and 1 year ]
  6. To assess the safety and tolerability of WST09-mediated VTP treatment in this patient population [ Time Frame: Day1,Day 7, Month1,3,6,and 12 ]
    The evaluation of safety will be based on reported adverse events, changes in vital signs and laboratory tests from the Treatment Visit until the study is completed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Histologically proven localized prostate cancer after receiving external radiation therapy;

Exclusion Criteria:

Patients unwilling or unable to give informed consent; Patients who received or are receiving chemotherapy; Patients previously treated with HIFU, cryotherapy, other salvage treatments, or with a trans-urethral resection of the prostate (TURP); Patients whose previous radiation therapy caused extensive cystitis and/or proctitis.

Patients suspected of Disseminated Intravascular Coagulation (DIC). Patients with prior history of coronary artery disease, angina pectoris, myocardial infarction, coronary angioplasty or coronary artery bypass graft, severe valvulopathy, cardiac failure, artrial fibrillation and / or sustained arrhythmia.

Patients whose cardiac status does not allow general anesthesia. Patients with history of thromboses or thrombo-embolisms. Patients with history of stroke or transient ischemic attack.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00312442


Locations
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
STEBA France
Investigators
Principal Investigator: John Trachtenberg, MD FRCS(C) University Health Network, Princess Margaret Hospital

Responsible Party: STEBA FRANCE
ClinicalTrials.gov Identifier: NCT00312442     History of Changes
Other Study ID Numbers: HEC/WST0512 66N/WST 2.21
First Posted: April 10, 2006    Key Record Dates
Last Update Posted: June 2, 2010
Last Verified: May 2010

Keywords provided by STEBA France:
Prostate cancer after radiation therapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases